Advances in the treatment of small vessel vasculitis

被引：24

作者：

Molloy, ES

Langford, CA

机构：

[1] Cleveland Clin Fdn, Dept Rheumat & Immunol Dis, Ctr Vasculittis Care & Res, Cleveland, OH 44195 USA

[2] Royal Coll Surgeons Ireland, Dept Clin Pharmacol, Dublin 2, Ireland

来源：

RHEUMATIC DISEASE CLINICS OF NORTH AMERICA | 2006年 / 32卷 / 01期

关键词：

D O I：

10.1016/j.rdc.2005.12.002

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The systemic small vessel vasculitides encompass Wegener's granulomatosis, microscopic polyangiitis, and Churg-Strauss syndrome. The traditional approach to therapy, which incorporates cytotoxic drugs and glucocorticoids, is associated with a significant risk of relapse and treatment-related toxicity. The formation of multicenter collaborative groups has facilitated the execution of randomized controlled trials, and has led to the identification of several effective therapeutic options. This article reviews the existing data and refers to studies in progress that may answer some of the questions that remain regarding the treatment of the systemic small vessel vasculitides.

引用

页码：157 / +

页数：17

共 92 条

[1]

ADU D, 1987, Q J MED, V62, P221

[2]

ALLEN NB, 1993, ADV EXP MED BIOL, V336, P473

[3] Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma [J].